Neumora Therapeutics, Common Stock Performance
| NMRA Stock | 1.56 0.01 0.65% |
The company secures a Beta (Market Risk) of 0.86, which conveys possible diversification benefits within a given portfolio. Neumora Therapeutics, returns are very sensitive to returns on the market. As the market goes up or down, Neumora Therapeutics, is expected to follow. At this point, Neumora Therapeutics, has a negative expected return of -1.5%. Please make sure to verify Neumora Therapeutics,'s accumulation distribution, as well as the relationship between the day typical price and relative strength index , to decide if Neumora Therapeutics, performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Neumora Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
1 | Disposition of 133097 shares by Paul Berns of Neumora Therapeutics, subject to Rule 16b-3 | 12/27/2024 |
2 | Acquisition by Burow Kristina of 1176593 shares of Neumora Therapeutics, subject to Rule 16b-3 | 01/31/2025 |
3 | Neumora Therapeutics, Inc. Sued for Securities Law Violations Investors Should Contact Levi Korsinsky for More Information NMRA | 02/13/2025 |
4 | NEUMORA THERAPEUTICS, INC. DEADLINE ALERT Bernstein Liebhard LLP Reminds Neumora Therapeutics, Inc. Investors of Upcoming Deadline | 02/18/2025 |
5 | Class Action Filed Against Neumora Therapeutics, Inc. ... | 02/20/2025 |
6 | Lowey Dannenberg Notifies Neumora Therapeutics, Inc. Investors of Securities Class Action Lawsuit and Encourages Investors with more than 100,000 in Losses to C... | 02/21/2025 |
7 | Neumora Therapeutics, Inc. Class Action Levi Korsinsky Reminds Neumora Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff De... | 02/24/2025 |
8 | Kessler Topaz Meltzer Check, LLP Reminds NMRA Investors of April 7, 2025 Deadline in Securities Fraud Class Action and Urges Investors with Losses to Contact th... | 02/25/2025 |
9 | Investors in Neumora Therapeutics, Inc. Should Contact The Gross Law Firm Before April 7, 2025 ... | 02/26/2025 |
10 | Acquisition by Michael Milligan of 85391 shares of Neumora Therapeutics, at 1.69 subject to Rule 16b-3 | 02/27/2025 |
11 | NMRA INVESTOR ALERT Bronstein, Gewirtz Grossman LLC Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class A... | 02/28/2025 |
| Begin Period Cash Flow | 242.2 M |
Neumora |
Neumora Therapeutics, Relative Risk vs. Return Landscape
If you would invest 980.00 in Neumora Therapeutics, Common on December 2, 2024 and sell it today you would lose (824.00) from holding Neumora Therapeutics, Common or give up 84.08% of portfolio value over 90 days. Neumora Therapeutics, Common is currently does not generate positive expected returns and assumes 11.2756% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Neumora, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Neumora Therapeutics, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neumora Therapeutics,'s investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Neumora Therapeutics, Common, and traders can use it to determine the average amount a Neumora Therapeutics,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1328
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NMRA |
Estimated Market Risk
| 11.28 actual daily | 96 96% of assets are less volatile |
Expected Return
| -1.5 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Neumora Therapeutics, is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Neumora Therapeutics, by adding Neumora Therapeutics, to a well-diversified portfolio.
Neumora Therapeutics, Fundamentals Growth
Neumora Stock prices reflect investors' perceptions of the future prospects and financial health of Neumora Therapeutics,, and Neumora Therapeutics, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Neumora Stock performance.
| Return On Equity | -0.7 | ||||
| Return On Asset | -0.35 | ||||
| Current Valuation | (86.53 M) | ||||
| Shares Outstanding | 161.56 M | ||||
| Price To Book | 0.79 X | ||||
| EBITDA | (187.53 M) | ||||
| Net Income | (235.93 M) | ||||
| Total Debt | 5.23 M | ||||
| Book Value Per Share | 2.00 X | ||||
| Cash Flow From Operations | (163.28 M) | ||||
| Earnings Per Share | (1.20) X | ||||
| Market Capitalization | 252.04 M | ||||
| Total Asset | 496.19 M | ||||
| Retained Earnings | (703.43 M) | ||||
| Working Capital | 453.17 M | ||||
About Neumora Therapeutics, Performance
By analyzing Neumora Therapeutics,'s fundamental ratios, stakeholders can gain valuable insights into Neumora Therapeutics,'s financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Neumora Therapeutics, has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Neumora Therapeutics, has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 7.78 | 7.39 | |
| Return On Tangible Assets | (0.43) | (0.45) | |
| Return On Capital Employed | (0.36) | (0.38) | |
| Return On Assets | (0.43) | (0.45) | |
| Return On Equity | (0.58) | (0.55) |
Things to note about Neumora Therapeutics, performance evaluation
Checking the ongoing alerts about Neumora Therapeutics, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Neumora Therapeutics, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Neumora Therapeutics, generated a negative expected return over the last 90 days | |
| Neumora Therapeutics, has high historical volatility and very poor performance | |
| Neumora Therapeutics, may become a speculative penny stock | |
| Net Loss for the year was (235.93 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Neumora Therapeutics, generates negative cash flow from operations | |
| Neumora Therapeutics, has a frail financial position based on the latest SEC disclosures | |
| About 72.0% of the company shares are owned by institutional investors | |
| Latest headline from globenewswire.com: NMRA INVESTOR ALERT Bronstein, Gewirtz Grossman LLC Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit |
- Analyzing Neumora Therapeutics,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Neumora Therapeutics,'s stock is overvalued or undervalued compared to its peers.
- Examining Neumora Therapeutics,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Neumora Therapeutics,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of Neumora Therapeutics,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Neumora Therapeutics,'s stock. These opinions can provide insight into Neumora Therapeutics,'s potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Neumora Stock analysis
When running Neumora Therapeutics,'s price analysis, check to measure Neumora Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neumora Therapeutics, is operating at the current time. Most of Neumora Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Neumora Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neumora Therapeutics,'s price. Additionally, you may evaluate how the addition of Neumora Therapeutics, to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |